MedTrace Logo

The iD2: A Smart Eye Drop Cap Monitor for Eye Drop Adherence

NCT07664943 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-06-24

No results posted yet for this study

Summary

Most patients with glaucoma use eye drops to lower their intraocular pressure. However, poor adherence to prescribed eye drop regimens can lead to significant loss of vision-related quality of life. This study will test the iDrop Device (iD2), a device-on-cap electronic platform monitor designed to accurately track when a research participant removes an eye drop bottle cap, wirelessly communicate usage data to a database accessible to researchers, and send on-demand alerts when a medication is due. A device capable of tracking eye drop usage and sending dosage alerts will test the hypothesis that electronic reminders improve medication adherence and help research subjects improve their eye drop taking behavior. While our primary focus is on glaucoma adherence, this device could also benefit those with other chronic eye conditions requiring regular eye drop treatment, such as dry eye, corneal endothelial disease, eye infections, and uveitis.

Conditions

Interventions

DEVICE

Eye drop cap monitor

Eye drop cap monitor for improving adherence

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • Universal Adherence LLC

    lead INDUSTRY

Principal Investigators

  • Steven Mansberger, MD, MPH · U n i v e r s a l A d h e r e n c e , L L C

  • Robert Kinast, MD · U n i v e r s a l A d h e r e n c e , L L C

  • Brian Breiling, MS, BS · U n i v e r s a l A d h e r e n c e , L L C

  • Vince O'Malley · U n i v e r s a l A d h e r e n c e , L L C

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-07-31
Completion
2027-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07664943 on ClinicalTrials.gov